Podcasts about genexpert

A tuberculose continua a ser um problema de saúde pública significativo em Angola. Em 2020, o Relatório Global sobre a Tuberculose da OMS indicava uma taxa de incidência de cerca de 361 casos por 100.000 habitantes no país, ou seja, uma das taxas mais altas do mundo. Em 2024, em Luanda, foram registados quase 29.000 casos de tuberculose e mais de 1.000 mortes. Neuza Lazzari, chefe do Departamento de Saúde Pública do Gabinete Provincial de Luanda, afirmou que a tuberculose está muitas vezes associada a condições deficientes de higiene e à falta de acesso a cuidados de saúde. Em 2024, em Luanda, foram registados quase 29.000 casos de tuberculose e mais de 1.000 mortes. Qual é a principal causa da elevada incidência de tuberculose na capital angolana?A tuberculose é uma doença infecciosa causada por uma bactéria, o Mycobacterium tuberculosis, transmitida pelo ar, que afecta principalmente os pulmões, mas pode também afectar outros órgãos.É preciso compreender que não há qualquer diferença entre a tuberculose que afecta os angolanos, actualmente, e a tuberculose diagnosticada em outros países.No entanto, a tuberculose está mais ligada a condições, principalmente deficientes, de higiene, e em Angola essa situação é mais frequente.Uma situação de pobreza, a falta de acesso a cuidados de saúde e condições de vida precárias contribuem para o aumento de casos de tuberculose?Sim. Sendo uma doença muito mais frequente em pessoas de nível socioeconómico baixo, a tuberculose também pode afectar pessoas com nível socioeconómico mais alto.Passo a explicar: eu posso ser uma pessoa pobre e trabalhar numa residência de alguém rico, mas com uma imunidade baixa. Nessa situação, essa pessoa está sob o risco de apanhar a doença, não porque vive em situação de pobreza, mas porque está exposta à contaminação, uma vez que se trata de uma doença provocada pelo contacto com as gotículas de saliva expelidas pela pessoa infectada.Por exemplo, as pessoas fumadoras, que têm HIV, pacientes que fazem diálise, com cancro e que tenham uma imunidade baixa são pessoas que podem ser facilmente contagiadas com a bactéria.Estas pessoas que acabou de citar fazem parte do grupo mais vulnerável, mas também há os idosos e as crianças…Exactamente. Também é uma doença muito comum nos serviços prisionais, devido ao aglomerado que lá se vive. São, muitas vezes, locais fechados, com pouca circulação de ar. Portanto, é também um grupo de risco.Quantas pessoas foram afetadas pela tuberculose em Luanda? Qual é a taxa de mortalidade associada a esta endemia?Posso apresentar apenas os dados relativos a 2024 na província de Luanda, lembrando que anteriormente a capital angolana tinha nove municípios e agora tem 16 municípios. No entanto, entre Janeiro e Dezembro de 2024, foram notificados 28.761 casos e registaram-se 1.040 óbitos neste período.Em 2023, foi apresentado um plano de luta contra a tuberculose. Estes números, que acabou de detalhar, significam que as medidas tomadas pelas autoridades falharam?Não! Se compararmos 2024 com 2023, houve uma redução do número de casos de tuberculose. Mas para nós, não obstante ter-se registado uma redução de casos, uma morte é sempre uma morte. O nosso objectivo é deixar de ter uma elevada taxa de incidência de tuberculose.No entanto, a saúde não trabalha sozinha. Existe a doença, existem os programas e existem os esforços do Governo para apetrechar as unidades e garantir a disponibilidade de medicamentos.Mas temos outros factores, como o da pobreza, fazendo com que a pessoa infectada acabe por infectar outras pessoas. Por isso, defendemos que as pessoas que vivem em condições de pobreza devem receber mais apoio social.Quais são as medidas do Governo para prevenir a tuberculose?Uma das coisas fundamentais, que é responsabilidade do Governo, é disponibilizar a vacina BCG desde a infância. Evitar os aglomerados, sabendo que em muitas residências que têm apenas um quarto e uma sala coabitam três ou quatro famílias. São estas condições que vemos não só na capital, na província de Luanda, mas também no interior do país.Por exemplo, as pessoas que têm a doença, mas que ainda não estão em tratamento, vão expelindo o bacilo e, se estiverem em contacto com outras pessoas, vão infetá-las. Por isso, essas pessoas devem usar máscara. Também deve ser feita uma busca activa nas comunidades, realizada pelos profissionais de saúde e também por agentes comunitários, para identificar as pessoas que têm a doença e que, por algum motivo, não estão a fazer a medicação. Essas pessoas devem ser encaminhadas para as unidades sanitárias para cumprirem o tratamento.O que acontece, muitas vezes, é que o paciente chega demasiado tarde ao hospital, ou então desenvolveu resistência ao antibiótico…Sim, e por isso fazemos palestras nas escolas, nas igrejas, nos mercados, nos serviços prisionais e nas instituições. Há um grupo da área de promoção da Saúde que faz essa sensibilização — todos os dias — nas unidades sanitárias. Os médicos e enfermeiros fazem uma pequena palestra matinal sobre os riscos que podem surgir para a saúde se não respeitarem o tratamento.Existe algum apoio internacional para combater esta doença?A nível da província de Luanda, temos a colaboração do Programa Nacional de Combate à Tuberculose e recebemos apoio técnico também da Organização Mundial da Saúde.Existe um plano para fortalecer o sistema de saúde em Luanda, para prevenir futuros casos de tuberculose?Existe o Plano Nacional definido pelo Ministério da Saúde de Angola para a província de Luanda. Temos consciência de que precisamos melhorar o diagnóstico laboratorial, principalmente com o GeneXpert [um sistema de diagnóstico molecular que utiliza a tecnologia PCR para detectar o DNA de micobactérias, incluindo o Mycobacterium tuberculosis], um aparelho que nem todas as unidades disponibilizam.Conhecendo o número de casos, associado à situação de extrema pobreza que se vive na província de Luanda, o GeneXpert seria um aparelho importante para detectar os casos de resistência múltipla, porque muitas vezes esses pacientes mudam de unidade sanitária e os técnicos de saúde não sabem se o paciente continua noutra unidade, se cancelou as consultas ou se abandonou o tratamento.Precisamos melhorar as estruturas das unidades de tratamento e diagnóstico. Enquanto província de Luanda, contávamos com a unidade do Centro de Endemias e Tratamento, a unidade que faz o internamento dos pacientes com tuberculose. Agora, com a nova divisão política, Luanda perdeu essa unidade. Continuamos a ter boas relações com a direcção da instituição, mas seria importante, a nível da província de Luanda, identificar outra unidade com capacidade similar para atender estes casos, para evitar as distâncias e diminuir a procura pelos serviços devido às distâncias. [Em 2024, a província de Luanda contava com 21 unidades de tratamento e 40 unidades de diagnóstico para a tuberculose].A tuberculose é uma doença tratável, se for diagnosticada precocemente. No entanto, continua a ser uma das doenças mais infecciosas e mortais em todo o mundo. Como se explica essa realidade?As condições socioeconómicas, de extrema pobreza, representam uma grande dificuldade na luta contra a tuberculose. Hoje em dia, em Angola, com os transtornos económicos e o encerramento de unidades privadas, principalmente após a pandemia de Covid, há uma maior procura pelos serviços públicos. Essa procura provoca uma sobrecarga do Serviço Nacional de Saúde.Confirma-se uma sobrecarga do Serviço Nacional de Saúde?Sim, a tuberculose é um problema, mas a malária é praticamente o prato do dia a dia, acabando por ser a principal causa não só de atendimento, como de internamento.

Dr. Stijn Deborggraeve is the Diagnostics Advisor Infectious Diseases at Médecins Sans Frontières (MSF) Access Campaign.In this episode we discussed GeneXpert technology including pricing, logistics, and future developments.

Mwaka 2020 Ghana iliripoti kuwa na watu 350,000 wanaioshi na virusi vya Ukimwi na kati yao hao 31,000 walikuwa ni wajawazito. Jambo lililoshtua ni kwamba ni sehemu ndogo mno ya wajawazito hao ndio walipimwa kufahamu iwapo wana VVU au la. Jambo lililofanya serikali kwa kushirikiana na shirika la Umoja wa Mataifa la kuhudumia watoto, UNICEF kuchukua hatua. Ripoti ya Assumpta Massoi inafafanua zaidi.

 - Trung tâm Kiểm soát bệnh tật (CDC) TP. Cần Thơ vừa tổ chức tập huấn và điều trị viêm gan C cho phòng khám ARV, methadone và cộng đồng. Hoạt động tập huấn này nằm trong nghiên cứu thí điểm tích hợp xét nghiệm tải lượng HCV (viêm gan C) và HIV vào hệ thống GeneXpert hiện có. Nghiên cứu được triển khai tại Trung tâm Y tế quận Nam Từ Liêm (Hà Nội) và Bệnh viện Đa khoa quận Thốt Nốt (Cần Thơ). Thời gian thí điểm từ tháng 3/2023 đến tháng 12/2024. Chủ đề : cần thơ, hiv --- Support this podcast: https://podcasters.spotify.com/pod/show/vov1tintuc/support

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test, published by Gemma Paterson on September 12, 2023 on The Effective Altruism Forum. Really great piece from Good Good Good on the campaign to pressure Danaher to reduce the price of their TB test. Excited to see the outcome! Tuberculosis is the world's deadliest disease - and it is entirely curable. The airborne disease has plagued human history, and the World Health Organization estimates that 10 million people across the globe are infected by TB every year. Of those millions, 1.6 million still die each year, despite the existence of life-saving technology and medicine. These are facts that enrage many - but especially author and philanthropist John Green. "Why am I passionate about TB? It's the deadliest disease in human history, but for most of human history we couldn't do much about it. However, since the mid-1950s, TB has been curable - yet we still allow TB to kill over 1.6 million people per year," Green told Good Good Good. "This is horrifying to me. I don't want to accept a world where we know how to cure Tuberculosis but deny millions of people access to that cure." This passion was put on display in July of this year. Through the social media campaign #PatientsNotPatents, Green and his fanbase - called Nerdfighters, or Nerdfighteria in collective form - followed the lead of TB advocates to call on drug company Johnson & Johnson to allow the sale of generic bedaquiline - a life-saving TB drug that had been inaccessible under the company's patent for over a decade. Nerdfighteria - as well as longtime TB organizations such as the Stop TB Partnership and TB-survivors Phumeza Tisile and Nandita Venkatesan - was successful, and Johnson & Johnson ended its reign on bedaquiline (though advocates are still working to ensure that all low- and middle-income countries receive access to the generic drug). To end the TB epidemic by 2030 - a goal shared by both the WHO and the United Nations - more pharmaceutical companies need to do their part to make healthcare more accessible, especially in countries with a high TB burden. So, in their effort to end TB, Nerdfighteria has taken on a new company: Danaher. The Issue Danaher is a multinational corporation, founded by brothers Steven and Mitchell Rales, that owns a number of other large companies, such as Cepheid, Pantone, and X-Rite. (Steven Rales also founded Indian Paintbrush Films, which has financed many of Wes Anderson's movies.) Most relevant to this campaign, however, is that in 2006, Danaher and molecular diagnostics company Cepheid created the most helpful diagnostic resource for TB: The GeneXpert machine. This rapid molecular testing machine is able to test for a number of infectious diseases, including COVID, HIV, TB, and multidrug-resistant TB. In fact, the WHO recommends Xpert tests as the initial test for all people with signs and symptoms of TB. The GeneXpert machine itself is cost-effective, but its testing cartridges are more costly. The company charges about $10 per regular TB testing cartridge and about $15 per multidrug-resistant TB testing cartridge (though both tests cost the same to manufacture). According to a 2019 brief from Doctors Without Borders, Danaher and Cepheid could reduce the cost of these cartridges to just $5 each - or lower - based on continuous increases in volume. The brief said a "20-30% reduction in price may be overdue" thanks to expansion in volume. "These pricing packages serve to expand Cepheid's footprint . and do nothing to address the urgent need to scale up affordable testing for COVID-19, TB, and other diseases, or to address the longstanding lack of affordability and unfair pricing of Xpert tests," David Branigan, of activist organization Treatment Action Group, said in a statement in 2...

No Dose de Ataque da vez, Mafê e Klinger discutem o Teste Rápido Molecular para Tuberculose, o famoso TRM-TB ou GeneXpert! Venha descobrir as indicações de realização do exame e as interpretações dos resultados!

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Bill Gates' 400 million dollar bet - First Tuberculosis Vaccine in 100 years?, published by NickLaing on July 2, 2023 on The Effective Altruism Forum. Last week a young man Onekalit turned up with a nasty cough to a health center we operate in a youth prison in Gulu, Northern Uganda. The dry cough wore him down for over a month, but last week he finally managed to cough a bit of sputum into a small plastic container. The incredible Gates Foundation funded GeneXpert test confimed our fears – Tuberculosis But Onekalit will be OK – after 6-9 months of gruelling treatment, the TB will be cured. He will not become one of the 1.5 million people that TB kills every year, more than double that of malaria. After covid subsided TB has now regained the dubious honour of the world's deadliest infectious disease. The Gates Foundation helped bring the amazing GeneXpert diagnostic test to places like rural Uganda, but Bill and co. are now going a step further making their biggest ever 400 million dollar bet on a vaccine that initial trials show may be 50% effective in stopping TB progress from latent infection to deadly lung disease. The first new effective TB vaccine in over 100 years.Surprisingly this vaccine has been sitting around (in a form) doing nothing much for around 20 years. GlaxoSmithKline (GSK) bought the patent almost 20 years ago, before publishing a trial which showed it was actually quite good and could save millions of lives, then decided they couldn't make money from the vaccine so shelved it... Crazy stuff. Unfortunately, our economic system is not set up to bring a vaccine which could save hundreds of millions of future lives to market. Fortunately our economic system does allow people like Effective Altruists and Bill Gates to donate their own stacks of cash towards life saving endeavours that the market has failed to bring to fruition. This mind bogglingly expensive 550million dollar trail is necessary because TB is a slow disease. Slow to divide, slow to spread, slow to treat. Tracking and follow up TB takes far longer than for your average infectious disease. For malaria, within a year we can start to see whether a vaccine works. For TB it will take at least 5 times as long – 5 years or more before we know whether we are onto a winner. If the vaccine really is 50% effective, it could save around 10 million lives in the next 25 years, not to mention helping prevent the terrifying Antimicrobial Resistance (AMR) that TB has already partly achieved. 500 million died from Smallpox (“but not a single one more”) – over 1 billion have died from TB. We remain far a from “not a single one more” in the case of TB – but this could be a spectacular step in the right direction. Not his real name Although from an effective altruism perspective the suffering caused by malaria is worse, because malaria kills mostly young children, whereas TB kills people of all ages. I'm not sure about this, please correct me if I'm wrong Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

Today I had the pleasure of speaking with Dr Emily MacLean about the exciting modern tests both commercially available and in research development for diagnosing tuberculosis. Emily talked to us about how GeneXpert has evolved and how we can get the most out of this amazing test but also about the extraordinary diagnostic tests being investigated at the moment from blood tests of host response to bacilli to AI learning cough acoustic markers of tuberculosis!REFERENCES:MacLean, Emily, et al. "Diagnostic accuracy of stool Xpert MTB/RIF for detection of pulmonary tuberculosis in children: a systematic review and meta-analysis." Journal of clinical microbiology 57.6 (2019): e02057-18.Singhroy, Diane N., et al. "Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers." Gates open research 4 (2020).MacLean, Emily Lai-Ho, et al. "Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study." The Lancet Microbe (2023).Zifodya, Jerry S., et al. "Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis." Cochrane Database of Systematic Reviews 2 (2021).APA | Mishra, Hridesh, et al. "Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study." The Lancet Respiratory Medicine 8.4 (2020): 368-382.APA | Kohli, Mikashmi, et al. "Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults." Cochrane Database of Systematic Reviews 1 (2021).APA | Branigan D. Tuberculosis Diagnostics. Nov 2022. Available at:https://www.treatmentactiongroup.org/wp-content/uploads/2022/11/pipeline_TB_diagnostics_2022.pdfMacLean, Emily, et al. "Advances in molecular diagnosis of tuberculosis." Journal of clinical microbiology 58.10 (2020): e01582-19.Sweeney, Timothy E., et al. "Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis." The Lancet Respiratory Medicine 4.3 (2016): 213-224.Sutherland, Jayne S., et al. "Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results." Clinical Infectious Diseases 74.12 (2022): 2136-2141.Moreira, Flora Martinez Figueira, et al. "Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study." EClinicalMedicine 33 (2021): 100776.Peter, Jonny G., et al. "Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial." The Lancet 387.10024 (2016): 1187-1197.

The LabOpp Global Leaders podcast is a series of conversations about Careers, the Lab Industry, Training, and People. As a wrap-up to Global MedLab Week, we wanted to ensure the final episode for this week be someone that has focused an extensive career on the profession and the development of those around her. We were pleased to be able to have Margaret Baekalia as our guest. Her journey in the field spans several countries, several roles and several decades (she began quite young!) If you would like to get in touch with Margaret, you can find her on LinkedIn. Some of the organizations/people mentioned during this podcast: · Fiji National University https://www.fnu.ac.fj/ · University of Otago https://www.otago.ac.nz/ · Ministry of Health & Medical Services Solomon Islands https://solomons.gov.sb/ministry-of-health-medical-services/ · Biofire https://www.biofiredx.com/ · GeneXpert https://www.cepheid.com/ If you have suggestions for future guests or comments about this podcast, please visit us at labopp.org/podcast/ Thank you for leaving a rating and review to help us share this podcast! --- Send in a voice message: https://podcasters.spotify.com/pod/show/labopp/message

Hace diez años se dió un avance importante cuando la OMS avaló la nueva prueba diagnóstica de la tuberculosis, gracias a la tecnología GeneXpert. Esta prueba molecular permite un diagnóstico rápido, en sólo dos horas y es fácil de utilizar. Un diagnóstico rápido es fundamental para que el paciente reciba el tratamiento adecuado y se pueda luchar contra esta enfermedad que cada año provoca la muerte de casi dos millones de personas en el mundo, principalmente en Asia y Africa. Los especialistas señalan que, con la invención de las nuevas pruebas diagnósticas de la tuberculosis, hay un antes y un después en la lucha contra esta enfermedad infecciosa. Y es que esta enfermedad provocada por una bacteria, contrariamente a lo que se pudiera creer, es la enfermedad infecciosa con mayor prevalencia en el mundo. Las cifras señalan que la tuberculosis afecta al 33 % de la población mundial en su forma latente, (sin síntomas) y​ es la segunda causa global de muerte y la primera entre las enfermedades infecciosas. Cada año casi dos millones de personas mueren por tuberculosis. El diagnóstico clásico se basa en radiografías del tórax, en una prueba de la tuberculina cutánea y análisis de sangre, así como un examen al microscopio y un cultivo microbiológico de los fluidos corporales como las expectoraciones. Pero este tipo de pruebas toman mucho tiempo en arrojar un resultado. El tratamiento para la tuberculosis por otra parte es complicado y requiere largos periodos de exposición con antibióticos y en los últimos años se ha observado un incremento en la resistencia a los medicamentos clásicos como la rifampicina. Por otra parte, son sobre todo en los países asiáticos y en África donde hay más casos de tuberculosis. Pruebas rápidas de diagnóstico Hace diez años, la creación de una nueva prueba rápida de diagnóstico cambió radicalmente la manera de enfrentar esta enfermedad. Pero aún falta mucho por hacer, comenzando por el acceso a estas pruebas, cuya tecnología lleva el nombre comercial de GeneXpert, sistema de diagnóstico molecular desarrollado por la empresa Cepheid. Entrevistada: la doctora Esther Casas, de Médicos sin Fronteras, especialista de VIH y tuberculosis en Sudáfrica. Escuchar aquí la entrevista:

Uncertainty continues in Samoa as the leaders of both major political parties claim to be the government; Health authorities in Fiji can now test almost 2000 people a day thanks to four new GeneXpert machines installed at the Nadi Hospital; Fiji women's football international Trina Davis is back with her family in the United States after a terrifying week trying to escape the conflict in Gaza.

Today on the show, we have Aalisha Sahu Khan and Professor Patrick Reading. Aalisha is the Head of Health Protection at the Fiji Ministry of Health and Medical Services, where she oversees a broad portfolio that includes environmental health, health emergencies and climate change and communicable disease control. Patrick is a scientist and educator at the WHO Collaborating Centre for Reference and Research on Influenza based at the Doherty Institute at the University of Melbourne. In this episode, Patrick talks about the Doherty Institute’s partnership with The Pacific Community, SPC, to increase laboratory capacity in Pacific Island countries to test for the SARS-CoV-2 virus that causes COVID-19.In addition, SPC has been working with the WHO Joint Incident management Team lab cell and the Pacific Islands Society for Pathology have been working on a protocol whereby up to 4 or 6 samples could be tested in in a single GeneXpert cartridge to scale up testing. Patrick will give us an update on Doherty’s support for this development.Aalisha reflects on the work that has gone into expanding the Fiji Centre for Disease Control's capacity to be able to test for the SARS-CoV-2 virus and what having domestic capacity has meant for preparedness and response. For more information about the Indo-Pacific Centre for Health Security, visit our website https://indopacifichealthsecurity.dfat.gov.auConnect with us on Twitter via @CentreHealthSec. We air an episode every fortnight so make sure you subscribe to receive our updates. Enjoy,Contain This Team

The Medical Laboratory Council of Nigeria (MLSCN) says it has not approved any Rapid Test Kits for the purpose of diagnosis and surveillance of Coronavirus (COVID-19) in the country. The Registrar and Chief Executive Officer of MLSCN, Dr Tosan Erhabor, stated this at a news conference on the Report of Pre-market Validation of SARS-COV-2 Infection (COVID-19) Rapid Test Kits in Nigeria on Friday in Abuja. According to the registrar, the council has validated four Rapid Test Kits and did not meet expected performance to be used in the country. Also speaking, Mrs Nwandu Mba, the Director of Laboratory Services, NCDC, emphasised that no rapid test kit had been approved for use in the country. “Even if we have rapid test kits approved later; it will only serve as a guide. We will still continue to use Polymerase Chain Reaction (PCR) for testing the virus,’’ she said. She said that NCDC was also working to validate GeneXpert machines for testing of COVID-19 to complement the PCR being currently used. (NAN) --- Send in a voice message: https://anchor.fm/mapradiong/message

I Tanzania används gambianska jättepåsråttor för att sniffa på tbc-sjukas hostprov och ställa diagnos. Samtidigt tränas hundar att nosa upp cancer. Men drömmen är en elektronisk näsa hos doktorn. Charles Joseph från Dar es Salaam fick veta på vårdcentralen Mbagala-Rangi Tatu att hans hostprov var negativt. Men några dagar senare hade organisationen Apopos råttor fått kontroll-lukta på slemmet och funnit tbc-doft. Nu går han på antibiotika som ska göra honom frisk. Dr. Lena Fiebig är chef för Apopos tbc-program i Tanzania, Etiopien och Mozambique säger att en råtta kan gå igenom 100 prov på 20 minuter vilket skulle tagit en labbassistent flera dagar att titta på i mikroskop som dessutom missar fler prov. Daniel Thobias på hjälporganisationen Mukikute ser sedan till att patienterna som fått en tbc-diagnos verkligen återvänder till vårdcentralen för medicin. Men statssekreteraren på hälsodepartementet narkosläkaren dr. Mpoki Ulisubisya tror mer på de dna-avläsningsapparater WHO rekommenderar som GeneXpert. Forskning pågår i många länder kring sjukdomslukt. CNN rapporterar om den israeliska e-näsan Na-nose från Technion som kan diagnosticera 17 sjukdomar och hur Medical Detection Dogs tillsammans med brittiska forskare undersöker hur bra hundar är på att upptäcka bröst- och prostatacancer. Amy Loutfi, professor i informationsteknologi vid Örebro Universitet har forskat om elektroniska näsor i vården och hon tror inte de slår igenom förrän om 30 år. Programmet är en repris från den 22 maj 2018. Johan Bergendorff global hälsokorrespondent Sveriges Radio johan.bergendorff@sr.se

I Tanzania används gambianska jättepåsråttor för att sniffa på tbc-sjukas hostprov och ställa diagnos. Samtidigt tränas hundar att nosa upp cancer. Men drömmen är en elektronisk näsa hos doktorn. Charles Joseph från Dar es Salaam fick veta på vårdcentralen Mbagala-Rangi Tatu att hans hostprov var negativt. Men några dagar senare hade organisationen Apopos råttor fått kontroll-lukta på slemmet och funnit tbc-doft. Nu går han på antibiotika som ska göra honom frisk. Dr. Lena Fiebig är chef för Apopos tbc-program i Tanzania, Etiopien och Mozambique säger att en råtta kan gå igenom 100 prov på 20 minuter vilket skulle tagit en labbassistent flera dagar att titta på i mikroskop som dessutom missar fler prov. Daniel Thobias på hjälporganisationen Mukikute ser sedan till att patienterna som fått en tbc-diagnos verkligen återvänder till vårdcentralen för medicin. Men statssekreteraren på hälsodepartementet narkosläkaren dr. Mpoki Ulisubisya tror mer på de dna-avläsningsapparater WHO rekommenderar som GeneXpert. Forskning pågår i många länder kring sjukdomslukt. CNN rapporterar om den israeliska e-näsan Na-nose från Technion som kan diagnosticera 17 sjukdomar och hur Medical Detection Dogs tillsammans med brittiska forskare undersöker hur bra hundar är på att upptäcka bröst- och prostatacancer. Amy Loutfi, professor i informationsteknologi vid Örebro Universitet har forskat om elektroniska näsor i vården och hon tror inte de slår igenom förrän om 30 år. Johan Bergendorff global hälsokorrespondent Sveriges Radio johan.bergendorff@sr.se

Hosts: Vincent Racaniello. Special guests: Laurene Mascola and David Persing Vincent meets up with Laurene and David at the Annual Meeting of the Southern California Branch of the American Society for Microbiology, where they discuss how the Los Angeles County Department of Health is preparing for an outbreak of Ebola virus infection, and Cepheid's game-changing, modular PCR system for the diagnosis of infectious diseases.

Hosts: Vincent Racaniello Guests: Laurene Mascola and David Persing Vincent meets up with Laurene and David at the Annual Meeting of the Southern California Branch of the American Society for Microbiology, where they discuss how the Los Angeles County Department of Health is preparing for an outbreak of Ebola virus infection, and Cepheid’s game-changing, modular PCR system for the diagnosis of infectious diseases.

Hosts: Vincent Racaniello. Special guests: Laurene Mascola and David Persing Vincent meets up with Laurene and David at the Annual Meeting of the Southern California Branch of the American Society for Microbiology, where they discuss how the Los Angeles County Department of Health is preparing for an outbreak of Ebola virus infection, and Cepheid’s game-changing, modular PCR system for the diagnosis of infectious diseases.

  Vincent meets up with Laurene and David at the Annual Meeting of the Southern California Branch of the American Society for Microbiology, where they discuss how the Los Angeles County Department of Health is preparing for an outbreak of Ebola virus infection, and Cepheid’s game-changing, modular PCR system for the diagnosis of infectious diseases.